Aurora, CONCT06512883Now EnrollingIRB Ready

Eosinophilic Granulomatosis With Polyangiitis (EGPA) Clinical Trial in Aurora, CO

Access cutting-edge eosinophilic granulomatosis with polyangiitis (egpa) treatment through this phase 3 clinical trial at a research site in Aurora. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Aurora location

Preparing your pre-screening questions…

Expert Care in Aurora

Access eosinophilic granulomatosis with polyangiitis (egpa) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related eosinophilic granulomatosis with polyangiitis (egpa) treatment provided free

Apply for This Aurora Location

Check if you qualify for this eosinophilic granulomatosis with polyangiitis (egpa) clinical trial in Aurora, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Aurora

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Aurora site if eligible
  4. 4Begin participation

About This Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study in Aurora

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

All Cohorts:
Male or female participants must be aged 6 to \< 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
Body weight greater than (\>=) 15 kilograms (kg). EGPA Cohort:
Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than \[\>\] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2). HES Cohort:
Documented HES diagnosis, defined as history of persistent eosinophilia \>1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
AEC ≥1000 cells/µL at screening (Visit 1).
Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.

Exclusion Criteria

All Cohorts:
Any current malignancy or history of malignancy.
History of anaphylaxis to any biologic therapy or vaccine.
Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
Previous receipt of benralizumab in an interventional clinical study. EGPA Cohort:
Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement. HES Cohort:
Life-threatening HES or HES complications, as judged by the investigator.
Hypereosinophilia of unknown significance (HE-US).
Diagnosis of systemic mastocytosis.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Aurora?

Yes, this clinical trial (NCT06512883) has an active research site in Aurora, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Eosinophilic Granulomatosis With Polyangiitis (EGPA) Treatment Options in Aurora, CO

If you're searching for eosinophilic granulomatosis with polyangiitis (egpa) treatment options in Aurora, CO, this clinical trial (NCT06512883) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Aurora research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced eosinophilic granulomatosis with polyangiitis (egpa) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all eosinophilic granulomatosis with polyangiitis (egpa) clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Aurora, CO

See all rheumatoid arthritis clinical trials recruiting in Aurora — not just this study.

Browse Rheumatoid Arthritis Trials in Aurora →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsVasculitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Aurora?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Aurora, CO